ASSERTIO THERAPEUTICS, INC. Deferred Tax Expense from Stock Options Exercised
ASSERTIO THERAPEUTICS, INC. reported Deferred Tax Expense from Stock Options Exercised of $5.20 million for the 12-month period ending 2015-12-31, per its 10-K filed 2017-02-24.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:DeferredTaxExpenseFromStockOptionsExercised · last filed 2017-02-24
- ASSERTIO THERAPEUTICS, INC. deferred tax expense from stock options exercised for fiscal 2015 was $5.20M, a 5.45% decline from fiscal 2014.
- ASSERTIO THERAPEUTICS, INC. deferred tax expense from stock options exercised for fiscal 2014 was $5.50M, a 17.02% increase from fiscal 2013.
- ASSERTIO THERAPEUTICS, INC. deferred tax expense from stock options exercised for fiscal 2013 was $4.70M.
| Period end | Deferred Tax Expense from Stock Options Exercised 12 month | Deferred Tax Expense from Stock Options Exercised 12 month as first filed |
|---|---|---|
| 2015-12-31 | $5.20M 10-K · filed 2017-02-24 | |
| 2014-12-31 | $5.50M 10-K · filed 2016-02-26 | |
| 2013-12-31 | $4.70M 10-K · filed 2015-02-26 | $4.50M 10-K · filed 2014-03-17 |